Search

Your search keyword '"Norrell, Jacqueline T"' showing total 5 results
Start Over Author "Norrell, Jacqueline T"
5 results on '"Norrell, Jacqueline T"'

1. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study

Author

Silk, Ann W., O’Day, Steven J., Kaufman, Howard L., Bryan, Jennifer, Norrell, Jacqueline T., Imbergamo, Casey, Portal, Daniella, Zambrano-Acosta, Edwin, Palmeri, Marisa, Fein, Seymour, Wu, Cai, Guerreiro, Leslie, Medina, Daniel, Bommareddy, Praveen K., Zloza, Andrew, Fox, Bernard A., Ballesteros-Merino, Carmen, Ren, Yixin, Shafren, Darren, Grose, Mark, Vieth, Joshua A., and Mehnert, Janice M.

Published
2023
Full Text
View/download PDF

2. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study

Author

Silk, Ann W., primary, O’Day, Steven J., additional, Kaufman, Howard L., additional, Bryan, Jennifer, additional, Norrell, Jacqueline T., additional, Imbergamo, Casey, additional, Portal, Daniella, additional, Zambrano-Acosta, Edwin, additional, Palmeri, Marisa, additional, Fein, Seymour, additional, Wu, Cai, additional, Guerreiro, Leslie, additional, Medina, Daniel, additional, Bommareddy, Praveen K., additional, Zloza, Andrew, additional, Fox, Bernard A., additional, Ballesteros-Merino, Carmen, additional, Ren, Yixin, additional, Shafren, Darren, additional, Grose, Mark, additional, Vieth, Joshua A., additional, and Mehnert, Janice M., additional

Published
2022
Full Text
View/download PDF

3. Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study

Author

Silk, Ann W., primary, O'Day, Steven J., additional, Kaufman, Howard L., additional, Bryan, Jennifer, additional, Norrell, Jacqueline T., additional, Imbergamo, Casey, additional, Portal, Daniella, additional, Zambrano-Acosta, Edwin, additional, Palmeri, Marisa, additional, Fein, Seymour, additional, Wu, Cai, additional, Guerreiro, Leslie, additional, Medina, Daniel, additional, Bommareddy, Praveen K., additional, Zloza, Andrew, additional, Fox, Bernard A., additional, Ballesteros-Merino, Carmen, additional, Shafren, Darren, additional, Grose, Mark, additional, Vieth, Joshua A., additional, and Mehnert, Janice M., additional

Published
2021
Full Text
View/download PDF

4. Clinical characterization of colitis arising from anti-PD-1 based therapy

Author

Wang, Daniel Y, primary, Mooradian, Meghan J, additional, Kim, DaeWon, additional, Shah, Neil J, additional, Fenton, Sarah E, additional, Conry, Robert M, additional, Mehta, Rutika, additional, Silk, Ann W., additional, Zhou, Alice, additional, Compton, Margaret L, additional, Al-Rohil, Rami N, additional, Lee, Sunyoung, additional, Voorhees, Amber L, additional, Ha, Lisa, additional, McKee, Svetlana, additional, Norrell, Jacqueline T, additional, Mehnert, Janice, additional, Puzanov, Igor, additional, Sosman, Jeffrey A, additional, Chandra, Sunandana, additional, Gibney, Geoffrey T, additional, Rapisuwon, Suthee, additional, Eroglu, Zeynep, additional, Sullivan, Ryan, additional, and Johnson, Douglas B, additional

Published
2018
Full Text
View/download PDF

5. Clinical characterization of colitis arising from anti-PD-1 based therapy.

Author

Wang, Daniel Y, Mooradian, Meghan J, Kim, DaeWon, Shah, Neil J, Fenton, Sarah E, Conry, Robert M, Mehta, Rutika, Silk, Ann W., Zhou, Alice, Compton, Margaret L, Al-Rohil, Rami N, Lee, Sunyoung, Voorhees, Amber L, Ha, Lisa, McKee, Svetlana, Norrell, Jacqueline T, Mehnert, Janice, Puzanov, Igor, Sosman, Jeffrey A, and Chandra, Sunandana

Subjects
MELANOMA, COLITIS, MEDICAL centers
Abstract

Colitis is a frequent, clinically-significant immune-related adverse event caused by anti-programmed death-1 (PD-1). The clinical features, timing, and management of colitis with anti-PD-1-based regimens are not well-characterized. Patients with advanced melanoma that received either anti-PD-1 monotherapy ("monotherapy") or combined with ipilimumab ("combination therapy") were screened from 8 academic medical centers, to identify those with clinically-relevant colitis (colitis requiring systemic steroids). Of 1261 patients who received anti-PD-1-based therapy, 109 experienced colitis. The incidence was 3.2% (30/937) and 24.4% (79/324) in the monotherapy and combination therapy cohorts, respectively. Patients with colitis from combination therapy had significantly earlier symptom onset (7.2 weeks vs 25.4 weeks, p < 0.0001), received higher steroid doses (median prednisone equivalent 1.5 mg/kg vs 1.0 mg/kg, p = 0.0015) and experienced longer steroid tapers (median 6.0 vs 4.0 weeks, p = 0.0065) compared to monotherapy. Infliximab use and steroid-dose escalation occurred more frequently in the combination therapy cohort compared to monotherapy. Nearly all patients had resolution of their symptoms although one patient died from complications. Anti-PD-1 associated colitis has a variable clinical presentation, and is more frequent and severe when associated with combination therapy. This variability in checkpoint-inhibitor associated colitis suggests that further optimization of treatment algorithms is needed. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results